|
Oveporexton was approved yesterday for treatment of narcolepsy type 1. ICER found that oveporexton (now branded Orzeyful) has at least a small, but likely substantial, net health benefit compared to no pharmacological treatment — resulting in an ICER evidence rating of B+.
ICER also stated that the treatment would meet common cost-effectiveness thresholds if priced between $50,400 and $59,400 per year. Takeda has not yet announced a price.
According to ICER's ICER’s Senior Vice President of Research, Foluso Agboola, MBBS, MPH:
“The narcolepsy treatment landscape includes several pricey medications that do not provide complete relief for patients. ICER’s analyses found that oveporexton, the first medication for narcolepsy type 1 that directly addresses the underlying cause of the condition, is effective in promoting wakefulness, improving quality of life, and appears to offer better health benefits than current options. The manufacturer choosing a value-based price for oveporexton would help de-escalate the cycle of high prices being met with onerous access challenges. Our independent analysis can offer a roadmap for improving affordability and access for patients and the health system.”
|